People with post-traumatic stress disorder (PTSD) may soon have a new treatment option: MDMA, the chemical found in ecstasy. In August, the Food and Drug Administration plans to decide whether MDMA-assisted therapy for PTSD will be approved for market based on years of research. But serious allegations of research misconduct may derail the approval timeline.
NPR science reporter
Will Stone talks to host
Emily Kwong about the clinical trials on MDMA-assisted therapy research and a recent report questioning the validity of the results.
Read Will's full story here. See
pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy
